Serum Exosomal miR-941 as a promising Oncogenic Biomarker for Laryngeal Squamous Cell Carcinoma
Serum Exosomal miR-941 as a promising Oncogenic Biomarker for Laryngeal Squamous Cell Carcinoma
复制标题
血清外泌体 miR-941 作为喉鳞状细胞癌有前景的致癌生物标志物
DOI：
10.7150/jca.45394
复制
发表时间：
2020-01-01
影响因子：
3.9
通讯作者：
Wang, Binquan
中科院分区：
文献类型：
--
作者：
Zhao, Qinli;Zheng, Xiwang;Wang, Binquan
目前，还没有基于血液的生物标志物用于喉鳞状细胞癌（LSCC）的临床实践。越来越多的证据表明，循环外泌体microRNAs（miRNAs）可作为各种癌症的潜在诊断生物标志物。本研究旨在鉴定和评估血清外泌体miRNAs用于喉鳞癌诊断。ExoQuick溶液（EQ）是一种高产且高效的外泌体分离方法，在本研究中被选择用于分离血清外泌体。在LSCC样品中，外泌体浓度高于健康对照（HC）样品。RNA-seq分析鉴定了总共1608个miRNAs，相对于HC样品，LSCC样品中有34个上调，41个下调。此外，qRT-PCR显示miR-941在LSCC血清外泌体中显著上调，在LSCC组织和细胞中观察到相同的趋势。此外，当在细胞系中检查miR-941时，miR-941过表达促进增殖和侵袭，而miR-941敲低抑制细胞增殖和侵袭。ROC曲线分析显示，miR-941用于区分LSCC患者和HC的曲线下面积（AUC）为0.797（95%CI = 0.676-0.918）。总之，血清外泌体miR-941可能作为一个有前途的致癌生物标志物，用于诊断喉鳞癌，并有潜力作为一个治疗靶点。
At present, no blood-based biomarkers have been used in clinical practice for laryngeal squamous cell carcinoma (LSCC). Increasing evidence suggests that circulating exosomal microRNAs (miRNAs) may serve as potential diagnostic biomarkers for various cancers. This study aims to identify and evaluate serum exosomal miRNAs for LSCC diagnosis. The ExoQuick solution (EQ), which provides a high-yield and is a highly efficient exosome isolation method, was selected to isolate serum exosomes in the current study. In LSCC samples, exosome concentrations were higher than in healthy control (HC) samples. RNA-seq analysis identified a total of 1608 miRNAs, with 34 upregulated and 41 downregulated in LSCC samples relative to HC samples. Furthermore, qRT-PCR showed that miR-941 is significantly upregulated in LSCC serum exosomes, with this same trend seen in LSCC tissues and cells. Moreover, when examining miR-941 in cell lines, miR-941 overexpression promoted proliferation and invasion, while miR-941 knockdown inhibited cell proliferation and invasion. ROC curve analysis showed that miR-941 has an area under the curve (AUC) of 0.797 (95% CI = 0.676-0.918) for distinguishing LSCC patients from HCs. In conclusion, serum exosomal miR-941 may serve as a promising oncogenic biomarker for diagnosing LSCC, and has the potential as a therapeutic target.